Skip to main content
Equibles
CRL logo

CRL · Charles River Laboratories International, Inc. · Metrics

Track CRL — free

Use CRL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$319.86 +4.41 (+1.40%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$15.06B
Shares
47.74M
Volume · Oct 20 1.27M Avg daily vol (3M) 943.43K

CRL metrics

102 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$315.45
Market cap
$15.06B

Price action

20 metrics
Price change (1W)
+5.5%
Price change (30D)
+13.1%
Price change (3M)
+43.8%
Price change (6M)
+72.3%
Price change (YTD)
+58.1%
Price change (1Y)
+71.3%
Trailing year
Price change (5Y)
-25.1%
52-week high
$315.45
52-week low
$149.93
Change from 52-week high
+0.0%
Change from 52-week low
+110.4%
Annualized volatility
45.1%
Annualized volatility (3M)
42.2%
Beta
1.2
RSI (14D)
64.9
Price vs SMA 50
+8.7%
Price vs SMA 200
+45.9%
Avg volume (3M)
943,427
Relative volume
1.4
Average dollar volume
$263.68M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
47.74M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.4×
reciprocal yield 22.9%
EV / EBITDA
45.1×
reciprocal yield 2.2%
EV / EBIT
194.1×
reciprocal yield 0.5%
P / sales
3.8×
reciprocal yield 26.6%
P / book
5.3
reciprocal yield 18.9%
FCF yield
2.5%
TTM · current market cap
Buyback yield
2.2%
P / FCF
40.6
reciprocal yield 2.5%
P / operating cash flow
25.9
reciprocal yield 3.9%
Earnings yield
-1.6%

Historical valuation

8 metrics
P / E historical average (3Y)
91.4×
reciprocal yield 1.1%
P / E historical average (5Y)
71.9×
reciprocal yield 1.4%
EV / revenue historical average (3Y)
2.9×
reciprocal yield 34.2%
EV / revenue historical average (5Y)
3.4×
reciprocal yield 29.5%
EV / EBIT historical average (3Y)
84.0×
reciprocal yield 1.2%
EV / EBIT historical average (5Y)
63.5×
reciprocal yield 1.6%
EV / EBITDA historical average (3Y)
18.7×
reciprocal yield 5.3%
EV / EBITDA historical average (5Y)
18.3×
reciprocal yield 5.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
2.3%
Trailing 12 months
Net margin
-6.0%
Gross profit (TTM)
$1.07B
Operating profit (TTM)
$90.14M
Net income (TTM)
−$238.46M
Trailing 12 months
Diluted EPS (TTM)
$-4.80
FCF margin
9.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$82.01
Gross profit per diluted share (TTM)
$21.19
Operating profit per diluted share (TTM)
$1.83
EBITDA per diluted share (TTM)
$7.93
Net income per diluted share (TTM)
$-4.92
Operating cash flow per diluted share (TTM)
$11.94
Free cash flow per diluted share (TTM)
$7.60
Capital expenditures per diluted share (TTM)
$4.34
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.70
Book value per share
$64.30

Growth

11 metrics
Revenue growth YoY
-2.7%
Year over year
Net income growth YoY
-102.8%
Revenue (TTM)
$4.00B
Trailing 12 months
EPS growth YoY
-102.8%
Shares change YoY
-2.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+0.3%
Revenue CAGR (5Y)
+6.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+20.7%
FCF CAGR (5Y)
+6.4%

Quality

14 metrics
Return on equity
-8.4%
Return on assets
-3.2%
Debt / equity
0.9
Current ratio
1.3
EBITDA (TTM)
$388.03M
Free cash flow (TTM)
$370.61M
Quick ratio
1.0
Interest coverage
0.8
Net debt / EBITDA
6.3
Return on invested capital
—
Trailing 12 months
Net cash
−$2.43B
Latest balance sheet
Cash & equivalents
$192.03M
Total assets
$7.53B
Total debt
$2.63B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$582.15M
Capital expenditures (TTM)
$211.54M
R&D (TTM)
—
SG&A (TTM)
$762.04M
Stock compensation (TTM)
$83.06M
R&D / revenue
—
Stock compensation / revenue
2.1%

Ownership (13F)

9 metrics
13F filers
572
13F filer change QoQ
+7
Institutional ownership
119.7%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.2%
Holder tenure
18.2
Price vs estimated holder cost
+25.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.2%

Short interest

3 metrics
Short interest
6.0%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$26.03M
Insider-sentiment score
26 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1100682 CUSIP 159864107 13F (30d) 84 filings 77 filers Visit website Investor relations